New radioactive treatment shows promise before prostate surgery
NCT ID NCT07208240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive drug called Tb-PSMA given before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if it is safe and helps improve surgical outcomes. About 20 participants will receive the drug and then undergo standard prostate removal surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beilinson Hospital
RECRUITINGPetah Tikva, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Man's best friend as cancer detector: can dogs sniff out prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- New scan could reveal hidden cancer in High-Risk prostate patients
- Promising prostate cancer combo trial pulled before starting
- New scan could revolutionize prostate cancer monitoring
- New immunotherapy combo targets High-Risk prostate cancer before and after surgery